RVMD Form 4: 25,000 sold at $48.5416; 25,000 exercised at $4.73

Revolution Medicines (RVMD) reported an insider transaction by an officer on 10/13/2025.

Rhea-AI Filing Summary

Revolution Medicines (RVMD) reported an insider transaction by an officer on 10/13/2025. The reporting person exercised 25,000 stock options at an exercise price of $4.73 per share, then sold 25,000 shares of common stock at a weighted average price of $48.5416. The trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.

Following these transactions, the reporting person beneficially owned 284,047 shares, which includes 84,000 restricted stock units, held directly. The filing also shows 5,055 derivative securities (stock options) remaining beneficially owned. The officer’s title is President, Research and Development.

Insider Trade Summary

Exercise and Sale: 25,000 shares ($1.10M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Kelsey Stephen Michael

Role See Remarks

Sold 25,000 shs ($1.21M)

Approx. gross sale proceeds $1.21M

Approx. exercise cost $118K

Approx. pre-tax spread $1.10M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,000	$0.00	$0.00
Exercise	Common Stock	25,000	$4.73	$118K
Sale	Common Stock	25,000	$48.5416	$1.21M

Holdings After Transaction: Stock Option (Right to Buy) — 5,055 contracts (Direct); Common Stock — 284,047 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
2. F2. Includes 84,000 restricted stock units.
3. F3. The transaction was executed in multiple trades in prices ranging from $48.03 to $48.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RVMD’s officer report on Form 4?

An exercise of 25,000 stock options at $4.73 and a sale of 25,000 shares at a $48.5416 weighted average on 10/13/2025.

Was the RVMD insider trade under a 10b5-1 plan?

Yes. The filing states trades were pursuant to a 10b5-1 plan adopted on February 28, 2025.

How many RVMD shares does the insider hold after the transaction?

Beneficial ownership is 284,047 shares, including 84,000 RSUs, held directly.

What prices were involved in the RVMD transactions?

Options were exercised at $4.73; shares were sold at a $48.5416 weighted average, with trades ranging from $48.03 to $48.99.

What derivative securities remain after the RVMD transactions?

The filing lists 5,055 derivative securities (stock options) beneficially owned following the transactions.

What is the officer’s role at RVMD?

The reporting person is President, Research and Development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kelsey Stephen Michael

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/13/2025		M(1)		25,000	A	$4.73	309,047(2)	D
Common Stock	10/13/2025		S(1)		25,000	D	$48.5416(3)	284,047(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.73	10/13/2025		M(1)			25,000	08/09/2023	08/08/2029	Common Stock	25,000	$0	5,055	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.

2. Includes 84,000 restricted stock units.

3. The transaction was executed in multiple trades in prices ranging from $48.03 to $48.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President, Research and Development

	/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.